Documentos para Download:

• DIR Acetato de Glatirâmer 40mg — Esclerose múltipla remitente recorrente
• DIR Acute stroke treatment in Europe: a questionnaire-based survey on behalf of the EFNS Task Force on acute neurological stroke care
• DIR A European Academy of Neurology guideline on medical management issues in dementia
• DIR Alentuzumabe — Esclerose múltipla remitente recorrente após falha terapêutica a duas ou mais terapias
• DIR Alentuzumabe — Esclerose múltipla remitente recorrente com características comparáveis aos critérios de tratamento com natalizumabe.
• DIR Alentuzumabe — Tratamento da esclerose múltipla remitente recorrente após falha terapêutica com betainterferona ou glatirâmer
• DIR Assessment and Management of Dysphagia in Children with Neurological Impairments (Best Practice 13(1))
• DIR Australian and New Zealand Living Clinical Guidelines for Stroke Management 
• DIR Australian Motor Neurone Disease (MND) Guideline
• DIR Betainterferonas — Esclerose múltipla remitente-recorrente (EMRR)
• DIR Canabidiol — Crianças e adolescentes com epilepsias refratárias aos tratamentos convencionais
• DIR Cladribina oral — Esclerose múltipla remitente-recorrente altamente ativa.
• DIR Cladribina oral — Tratamento de pacientes com esclerose múltipla remitente-recorrente altamente ativa
• DIR Clinical Medication Guidelines for Geriatric Peripheral Neuropathic Pain
• DIR Clinical Practice Guideline for the Management of Cerebral Small Vessel Disease
• DIR Clinical practice guideline for the Management of Patients with Parkinson´s Disease
• DIR Clinical Practice Guideline for the Prevention and/or Treatment of Chemotherapy-Induced Peripheral Neuropathy using Natural Health Products
• DIR Clinical practice guidelines for surgery in patients with tuberous sclerosis complex-related epilepsy
• DIR Clinical Practice Guidelines for The Diagnosis and Treatment of Diffuse Glioma-Related Epilepsy: 2025 update
• DIR Cloridrato de fingolimode — Primeira linha de pacientes com esclerose múltipla remitente recorrente, de baixa e moderada atividade, em troca entre os medicamentos de primeira linha ou virgens de tratamento
• DIR Cloridrato de memantina — Alzheimer moderada e grave em pacientes com disfagia
• DIR Clozapina — Psicose associada à doença de Parkinson
• DIR Composto nutricional — Melhora de memória em pacientes com doença de Alzheimer na fase leve
• DIR DESIGN OF AN INTERACTION PROTOCOL BETWEEN PRIMARY CARE AND HOSPITALS TO IMPROVE EARLY DETECTION AND MONITORING OF PATIENTS WITH MULTIPLE SCLEROSIS
• DIR Diagnosis and drugs consumption for Alzheimer's disease in the Basque Country
• DIR Diagnosis and management of epilepsy in adults (SIGN CPG 143)
• DIR Dicloridrato de pramipexol — Liberação prolongada para parkinson idiopática em fase inicial ou avançada
• DIR Doença de Alzheimer
• DIR Doença de Parkinson
• DIR Donepezila — Pacientes com doença de Alzheimer grave
• DIR Duloxetina — Dor neuropática e da fibromialgia
• DIR EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke
• DIR EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guideline on palliative care of people with severe, progressive multiple sclerosis
• DIR EAN guidelines on central neurostimulation therapy in chronic pain conditions
• DIR ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
• DIR ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
• DIR EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
• DIR EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease
• DIR EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force
• DIR EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force
• DIR EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force
• DIR EFNS guideline on the management of status epilepticus
• DIR EFNS guideline on the management of status epilepticus in adults
• DIR EFNS guideline on the treatment of tension-type headache – Report of an EFNS task force
• DIR EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses
• DIR EFNS guidelines for the diagnosis and management of Alzheimer’s disease
• DIR EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases
• DIR EFNS guidelines on management of narcolepsy
• DIR EFNS guidelines on neuropathic pain assessment: revised 2009
• DIR EFNS guidelines on neurostimulation therapy for neuropathic pain
• DIR EFNS guidelines on pharmacological treatment of neuropathic pain
• DIR EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force
• DIR EFNS guidelines on the molecular diagnosis of channelopathies, epilepsies, migraine, stroke, and dementias
• DIR EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias
• DIR EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
• DIR EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis
• DIR EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
• DIR EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy
• DIR EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives
• DIR EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases First of two parts
• DIR EFNS task force on molecular diagnosis of neurologic disorders Guidelines for the molecular diagnosis of inherited neurologic diseases Second of two parts
• DIR EFNS Task Force on postgraduate neurological training Survey of the current situation of postgraduate neurological training in Europe
• DIR EFNS Task Force on Teaching of Neuroimaging in Neurology Curricula in Europe: present status and recommendations for the future
• DIR Epilepsia
• DIR Epilepsies in children, young people and adults
• DIR Epilepsies in children, young people and adults
• DIR Epilepsies in children and young people: Investigative procedures and management (SIGN CPG 159)
• DIR Esclerose Múltipla
• DIR Estimulação elétrica do nervo vago — Terapia adjuvante de pacientes pediátricos com epilepsia resistente a medicamentos, sem indicação para cirurgia ressectiva de epilepsia
• DIR Estimulação elétrica do nervo vago na terapia adjuvante — Farmacológico em crianças e adultos com epilepsia focal ou generalizada refratária a pelo menos dois esquemas com medicamentos anticonvulsivantes para epilepsia
• DIR European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD)
• DIR European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies
• DIR European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision
• DIR European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
• DIR European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
• DIR European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke
• DIR European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness
• DIR European Academy of Neurology guideline on the management of medication-overuse headache
• DIR European Academy of Neurology guideline on trigeminal neuralgia
• DIR European Academy of Neurology guidelines on the treatment of cluster headache
• DIR European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy*
• DIR European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Socie
• DIR European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Ne
• DIR European guideline and expert statements on the management of narcolepsy in adults and children
• DIR European guideline and expert statements on the management of narcolepsy in adults and children
• DIR European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society
• DIR European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment
• DIR Fingolimode — Esclerose múltipla
• DIR Fingolimode — Esclerose múltipla
• DIR Fingolimode — Esclerose múltipla remitente recorrente após falha terapêutica com betainterferona ou glatirâmer
• DIR Fumarato de dimetila — Esclerose múltipla remitente-recorrente após a 1ª falha terapêutica
• DIR Fumarato de dimetila — Esclerose múltipla remitente recorrente após falha com betainterferona ou glatirâmer
• DIR Fumarato de dimetila — Primeira linha da esclerose múltipla remitente recorrente
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004*
• DIR Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012
• DIR Guidelines by the European Federation of Neurological Societies (EFNS) subcommittee for Continuing Medical Education (CME) – modification 2003
• DIR Guidelines for Specialized Epilepsy Centers. Executive Summary of the Report of the National Association of Epilepsy Centers Guideline Panel
• DIR Guidelines on use of anti-IFN-B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-B antibodies in multiple sclerosis
• DIR Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis
• DIR ​Headache in adult
• DIR Headaches in over 12s
• DIR Headaches in over 12s: diagnosis and management
• DIR Identification and Management of Dysphagia in Children with Neurological Impairment (Best Practice 4(3))
• DIR Joint European Academy of Neurology–European Pain Federation–Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment
• DIR KNGF Guideline for Physical Therapy in patients with Parkinson's disease
• DIR Lacosamida — Terapia aditiva em pacientes com epilepsia focal refratários aos tratamentos prévios com os fármacos antiepilépticos disponíveis no SUS
• DIR Levetiracetam (500 mg e 1000 mg) — Tratamento adjuvante para epilepsia
• DIR Levetiracetam — Convulsões em pacientes com microcefalia
• DIR Levetiracetam — Epilepsia
• DIR Levetiracetam — Terapia adjuvante em pacientes com epilepsia mioclônica juvenil resistentes à monoterapia
• DIR Levetiracetam em monoterapia — Epilepsia focal em pacientes com falha no tratamento com carbamazepina
• DIR Lidocaína — Dor neuropática localizada
• DIR Management of Ischaemic Stroke (2nd Edition)
• DIR Management of Multiple Sclerosis
• DIR Management of paraneoplastic neurological syndromes: report of an EFNS Task Force
• DIR Memantina — Doença de Alzheimer
• DIR Mesilato de bromocriptina — Doença de Parkinson e de hiperprolactinemia.
• DIR Mesilato de rasagilina em combinação com levodopa — Doença de Parkinson com complicações motoras
• DIR Miglustate — Manifestações Neurológicas da Doença de Niemann-Pick Tipo C (NPC)
• DIR Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas: Guideline From the College of American Pathologists in Collaboration With the American Association of Neuropathologists, Association for Molecular Pathology, and Society for Neuro-Oncology
• DIR Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology
• DIR Monogenic cerebral small‐vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology
• DIR Motor neurone disease
• DIR Motor neurone disease: assessment and management
• DIR Multiple sclerosis
• DIR Multiple sclerosis in adults: management
• DIR Natalizumabe — Esclerose múltipla remitente-recorrente com alta atividade de doença
• DIR Natalizumabe 300mg — Esclerose múltipla
• DIR National clinical guideline for stroke for the UK and Ireland (SIGN CPG 166)
• DIR Neuropathic pain in adults: pharmacological management in non-specialist settings
• DIR Neurophysiological tests and neuroimaging procedures in non-acute headache: guidelines and recommendations
• DIR Ocrelizumabe — Adultos com esclerose múltipla remitente-recorrente (EMRR) como alternativa ou contraindicação ao natalizumabe
• DIR Ocrelizumabe — Esclerose Múltipla primariamente
• DIR Ocrelizumabe — Recorrencia de Esclerose Múltipla
• DIR Ofatumumabe em primeira linha de terapia modificadora do curso da doença — Tratamento da esclerose múltipla recorrente
• DIR Parkinson's disease
• DIR Parkinson's disease in adults
• DIR PET Imaging in Paraneoplastic Neurological Syndromes 18
• DIR Pharmacological management of migraine (SIGN CPG 155)
• DIR Pharmacological treatment of migraines. Qualitative study
• DIR Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians
• DIR Pregabalina — Dor neuropática e fibromialgia
• DIR Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
• DIR Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Alzheimer
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Alzheimer
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Parkinson
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Doença de Parkinson
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Epilepsia
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Esclerose Múltipla
• DIR QUALITY OF LIFE OF STROKE PATIENTS AND THEIR CAREGIVERS. PROGNOSIS AND RESULTS OF REHABILITATING TREATMENT
• DIR Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
• DIR Report of an EFNS task force on management of sleep disorders in neurologic disease (degenerative neurologic disorders and stroke)
• DIR Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's dise
• DIR Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease
• DIR Rivastigmina — Doença de Parkinson e demência
• DIR Rivastigmina adesivo transdérmico — Demência para Doença de Alzheimer
• DIR Rivastigmina via transdérmica (adesivo) — Demência leve e moderadamente grave do tipo Alzheimer
• DIR Selegilina — Doença de Parkinson
• DIR Selegilina 10 mg — Doença de Parkinson
• DIR Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
• DIR Stroke in adults
• DIR Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
• DIR Suspected neurological conditions: recognition and referral
• DIR Suspected neurological conditions: recognition and referral
• DIR Systematic Review and Evidence-Based Guidelines for Occipital Nerve Stimulation for the Treatment of Patients With Medically Refractory Occipital Neuralgia Update
• DIR Teriflunomida — Primeira linha de tratamento da esclerose múltipla remitente recorrente
• DIR The Diagnosis & Management of Stroke and Transient Ischaemic Attack
• DIR The Utility of Positron Emission Tomography in Epilepsy 13
• DIR Tolcapona 100 mg — Doença de Parkinson
• DIR Traditional Chinese Medicine treatment guideline for primary headache disorders(NGC: 011363)
• DIR Treatment of medication overuse headache – guideline of the EFNS headache panel
• DIR Treatment of miscellaneous idiopathic headache disorders (group 4 of the IHS classification) – Report of an EFNS task force
• DIR When to order CT/MRI for headache

Documentos para Download:

• PDF Cistite intersticial - tratamento oral
• PDF Disfunções neurológicas do trato urinário inferior
• PDF Litíase urinária – investigação diagnóstica
• PDF Disfunção erétil tratamento medicamentoso
• PDF Infecções sexualmente transmissíveis (ist) : diagnóstico laboratorial
• PDF Litíase urinária - avaliação do uso da litotripsia ureteral a laser versus pneumática
• PDF Litíase urinária - cirurgia convencional aberta
• PDF Bexiga hiperativa tratamento farmacológico
• PDF Cistite intersticial - Diagnóstico
• PDF Adrenalectomia laparoscópica total e parcial
• PDF Hiperplasia prostática benigna – tratamento minimamente invasivo
• PDF Esfíncter artificial na incontinência urinária masculina - Abordagem escrotal versus perineal
• PDF Esfíncter artificial na incontinência urinária masculina - Cuidados peri e pós-operatório
• PDF Hiperplasia Prostática Benigna - Terapia Minimamente Invasiva
• PDF Hiperplasia Prostática Benigna - Tratamento
• PDF Hiperplasia Prostática Benigna - Prostatectomia por vaporização a laser
• PDF Biópsia Renal Laparoscópica
• PDF Nefrectomia do Doador Vivo
• PDF Adenocarcinoma Metastático De Próstata Resistente À Castração
• PDF Esfíncter Artificial Na Incontinência Urinária Masculina
• PDF Esfíncter Artificial Na Incontinência Urinária Masculina Modelo Ams 800
• PDF Esfíncter Artificial Na Incontinência Urinária Masculina Pré-Operatório
• PDF Esfíncter Urinário Artificial - Abordagem Transcorporal Para O Cuff
• DIR Acetato de ciproterona — Pacientes com adenocarcinoma de próstata resistente à castração
• DIR Adenocarcinoma de Próstata
• DIR ATOMs – Adjustable Transobturator Male System. Device for urinary incontinence
• DIR Bladdercarcinoma
• DIR Cateter hidrofílico — Cateterismo vesical intermitente em indivíduos com lesão medular e bexiga neurogênica
• DIR Darifenacina — Disfunção de armazenamento em pacientes com bexiga neurogênica
• DIR Darifenacina — Incontinência urinária de urgência (IUU)
• DIR Diretrizes Diagnósticas e Terapêuticas — Adenocarcinoma de Próstata
• DIR Effectiveness of a pelvic floor muscle exercise program on urinary incontinence following childbirth (Best Practice 9(2))
• DIR Esfíncter urinário artificial — Incontinência urinária masculina grave pós-prostatectomia
• DIR European Academy of Neurology (EAN)/European Federation of Autonomic Societies (EFAS)/International Neuro-Urology Society (INUS) Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Gui
• DIR Faecal incontinence in adults
• DIR Faecal incontinence in adults: management
• DIR Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management 17-3V2
• DIR Identificação de glicídios urinários por cromatografia (camada delgada) — Doenças Raras
• DIR Identificação de glicosaminoglicanos urinários por cromatografia em camada delgada, eletroforese e dosagem quantitativa — Doenças Raras
• DIR Implante de esfíncter urinário artificial — Incontinência urinária grave pós-prostatectomia radical
• DIR Incontinência Urinária não Neurogênica
• DIR KNGF Evidence Statement Anal Incontinence
• DIR Lower urinary tract symptoms in men
• DIR Lower urinary tract symptoms in men: management
• DIR Mirabegrona — Disfunção de armazenamento em pacientes com bexiga neurogênica
• DIR Mirabegrona — Incontinência urinária de urgência (IUU)
• DIR Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline From the American College of Physicians
• DIR Oxibutinina — Disfunção de armazenamento em pacientes com bexiga neurogênica
• DIR Oxibutinina — Incontinência urinária de urgência (IUU)
• DIR Prostatectomia radical assistida por robô — Câncer de próstata localizado
• DIR Prostatectomia radical assistida por robô — Pacientes com câncer de próstata clinicamente localizado ou localmente avançado
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Incontinência Urinária não Neurogênica
• DIR Recommandations sur le dépistage du cancer de la prostate par le dosage de l’antigène prostatique spécifique
• DIR Sistema cirúrgico robótico — Cirurgia minimamente invasiva: Prostatectomia radical
• DIR Solifenacina — Disfunção de armazenamento em pacientes com bexiga neurogênica
• DIR Solifenacina — Incontinência urinária de urgência (IUU)
• DIR Strategies to promote intermittent self-catheterization in adults with neurogenic bladders (Best Practice 15(7))
• DIR Tolterodina — Disfunção de armazenamento em pacientes com bexiga neurogênica
• DIR Tolterodina — Incontinência urinária de urgência (IUU)
• DIR Toxina Botullínica — Bexiga hiperativa
• DIR Ureterolitotripsia transureteroscópica — Litíase do trato urinário
• DIR Urinary incontinence and pelvic organ prolapse in women: management
• DIR Urinary incontinence in neurological disease: assessment and management
• DIR Urinary incontinence in women